Status In progress
Process CDF Review
ID number 1635

Provisional Schedule

Committee meeting: 1 14 July 2021
Expected publication 22 September 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Takeda UK (ixazomib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Myeloma UK
Professional groups Royal College of Pathologists
  Royal College of Physicians
  UK Myeloma Forum

Commentators

Comparator companies Advanz pharma (dexamethasone) – confidentiality agreement not signed, not participating
  Aspen (dexamethasone) – confidentiality agreement not signed, not participating
  Aspire pharma (bortezomib, dexamethasone) – confidentiality agreement not signed, not participating
  Celgene (lenalidomide)
  Consilient health (dexamethasone) – confidentiality agreement not signed, not participating
  Dr Reddy’s laboratories (bortezomib) – confidentiality agreement not signed, not participating
  Focus Pharmaceuticals (dexamethasone) – confidentiality agreement not signed, not participating
  Glenmark pharmaceuricals (dexamethasone) – confidentiality agreement not signed, not participating
  Janssen-Cilag (bortezomib)
  Martindale pharma (dexamethasone) – confidentiality agreement not signed, not participating
  Mylan (bortezomib) – confidentiality agreement not signed, not participating
  Rosemont pharmaceuticals limited (dexamethasone) – confidentiality agreement not signed, not participating
  Secura Bio (panobinostat)
  Teva (dexamethasone)
  Thornton & Ross (bortezomib) – confidentiality agreement not signed, not participating
  Zentiva (bortezomib) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
10 March 2021 Invitation to participate
10 March 2021 In progress. ITP now due

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance